Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Save on this medicine
Same active ingredient — pay up to 52% less
These brands contain the same active ingredient (Gefitinib). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Gefinix is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Recommended dose: 250 mg Gefitinib taken by mouth once daily, with or without food, continued until disease progression or unacceptable toxicity. A missed dose should not be taken within 12 hours of the next dose. Administration to patients who have difficulty swallowing solids: Drop the Gefitinib tablet into 4 to 8 ounces of water and stir for approximately 15 minutes. The liquid should be drunk immediately or administered through a naso-gastric tube. Rinse the container with another 4 to 8 ounces of water, and drink this immediately or administer it through the naso-gastric tube.
Side Effects
The most common side effects of this tablet are interstitial lung disease, liver toxicity (hepatotoxicity), gastrointestinal perforation, severe or persistent diarrhea, ocular (eye) disorders including keratitis, and bullous and exfoliative skin disorders.
Cautions & Contraindications
Warnings & Precautions
Interstitial lung disease (ILD): ILD or ILD-like adverse drug reactions (for example lung infiltration, pneumonitis, acute respiratory distress syndrome, or pulmonary fibrosis) occurred in 1.3% of the 2462 patients who received Genib across clinical trials. Genib should be withheld and the patient promptly investigated for ILD whenever respiratory symptoms such as dyspnea, cough and fever get worse. It should be permanently discontinued if ILD is confirmed. Hepatotoxicity: Among patients receiving Genib across clinical trials, 11.4% had increased alanine aminotransferase (ALT), 7.9% had increased aspartate aminotransferase (AST), and 2.7% had increased bilirubin. Liver function tests should be carried out periodically. Genib should be withheld in patients with worsening liver function and discontinued in patients with severe hepatic impairment. Gastrointestinal perforation: Gastrointestinal perforation occurred in three (0.1%) of the 2462 Genib-treated patients across clinical trials. It should be permanently discontinued in patients who develop gastrointestinal perforation. Severe or persistent diarrhea: Grade 3 or 4 diarrhea occurred in 3% of the 2462 Genib-treated patients across clinical trials. It should be withheld for severe or persistent (up to 14 days) diarrhea. Ocular disorders including keratitis: Ocular disorders, namely keratitis (0.1%), corneal erosion and aberrant eyelash growth (0.2%), and conjunctivitis, blepharitis and dry eye (6.7%), occurred in the 2462 Genib-treated patients across clinical trials. It should be interrupted or discontinued for severe or worsening ocular disorders. Bullous and exfoliative skin disorders: Bullous conditions including toxic epidermal necrolysis, Stevens Johnson syndrome and erythema multiforme have been reported with Genib treatment. Erythema multiforme and dermatitis bullous have been reported in two patients (0.08%) across NSCLC trials. Genib treatment should be interrupted or discontinued if the patient develops severe bullous, blistering or exfoliating conditions.
Contraindications
Gefitinib must not be used in patients with a known hypersensitivity (allergy) to Gefitinib or to any of the other ingredients in this medicine.